Skip to contentM
MapLight Therapeutics, Inc.
M
MPLTMapLight Therapeutics, Inc. MPLT Q3 2025 · MapLight Therapeutics, Inc. · ThalerReleased Dec 4, 2025, before the open
10-Q filed Dec 4, 2025, 65 days after period end · 0001193125-25-307453
Q3 2025 · 10-Q
Revenue—
Net Income-$29.42M-$29.42MN/M vs Q3 2024N/M vs Q2 2025 EPS Diluted-$37.18-$37.18
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MapLight Therapeutics, Inc. · CIK 1770069 · Engraved from SEC EDGAR
N/M vs Q2 2025
Operating Income-$31,498,000N/M Operating Cash Flowderived-$31,791,000— Free Cash Flowderived-$31,822,000— ended Sep 30, 2025 · filed Dec 4, 2025 · 65 d after period end
+8.2% from the close of Dec 3, 2025 to the close of Dec 4, 2025, the first after the release.
before the open$16.92$18.30 Nov 11Dec 4Dec 26